Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8
By Sriparna Roy
Sept 27 (Reuters) -The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
The health regulator has cleared the drug's use as an add-on treatment for some adults with inadequately controlled chronic obstructive pulmonary disease (COPD), a condition that progressively damages the lungs and causes restricted airflow.
Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U.S. and other countries.
The company has said it expects the target COPD patient population eligible for the drug to be roughly 300,000 patients in the U.S. It has anticipated steeper growth in Dupixent sales in 2025 after the launch for COPD in the country.
Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in revenue in 2030, according to estimates compiled by LSEG. BMO Capital Markets analyst Evan Seigerman in May estimated the drug's peak sales in COPD to reach $2.9 billion in the same year.
COPD, which is the fourth leading cause of death globally, is a lifelong condition that commonly affects cigarette smokers but can also be caused by air pollution and related occupational hazards.
In July, the European Union approved the use of the drug in patients who cannot be helped by standard inhaled treatments for the potentially deadly disease.
In late-stage trials, the drug significantly reduced the moderate or severe exacerbations and also helped to significantly improve lung function, compared to a placebo.
Shares of Regeneron were trading 2.5% higher in morning trade.
Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Sriraj Kalluvila
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
